Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop

Antonio Ceriello, Helena W. Rodbard, Tadej Battelino, Frank Brosius, Francesco Cosentino, Jennifer Green, Linong Ji, Monika Kellerer, Susan Koob, Mikhail Kosiborod, Nebojsa Lalic, Nikolaus Marx, T. Prashant Nedungadi, Christopher G. Parkin, Lars Rydén, Wayne Huey Herng Sheu, Eberhard Standl, Per Olav Vandvik, Oliver Schnell

Research output: Contribution to journalComment/debatepeer-review

Abstract

In recent years, several novel agents have become available to treat individuals with type 2 diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA)/glucagon-like peptide-1 receptor agonist (GLP-1 RA), and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA) that confers significant renal and cardiovascular benefits in individuals with (CKD). New medications have the potential to improve the lives of individuals with diabetes. However, clinicians are challenged to understand the benefits and potential risks associated with these new and emerging treatment options. In this article, we discuss how use of network meta-analyses (NMA) can fill this need.

Original languageEnglish (US)
Article number277
JournalCardiovascular Diabetology
Volume22
Issue number1
DOIs
StatePublished - Dec 2023
Externally publishedYes

Keywords

  • (GIP RA)
  • Finerenone
  • Glucagon-like peptide-1 receptor agonist (GLP-1 RA)
  • Glucose-dependent insulinotropic polypeptide
  • Network meta-analysis
  • Randomized controlled trial
  • Sodium glucose cotransporter 2 inhibitor
  • Tirzepatide

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop'. Together they form a unique fingerprint.

Cite this